Alex M. Azar, II net worth and biography

Alex Azar, II Biography and Net Worth

Director of Guardant Health

Alex M. Azar II has served as a member of Guardant Health’s Board of Directors since September 2025. Alex M. Azar II served as the 24th Secretary of the U.S. Department of Health and Human Services (HHS) from 2018 to 2021. Prior to his appointment as HHS Secretary, Secretary Azar held multiple executive leadership roles including as President of Lilly USA, LLC, the largest affiliate of Eli Lilly and Company, from 2007 to 2017, and Deputy Secretary of HHS from 2005 to 2007, General Counsel of HHS from 2001 to 2005, and Partner at Wiley Rein LLP from 1999 to 2001. He currently serves as an Adjunct Professor of Business and Distinguished Executive-in-Residence at the University of Miami Herbert Business School.

Secretary Azar is a member of the Board of Trustees at the Aspen Institute, Chair of the Board of the Healthcare Leadership Council, Chair of the Board of LifeScience Logistics, and a member of the Board of Directors of Global Health/MCS and AbsoluteCare. He also serves as an advisor at Foresite Capital, a member of the advisory board of Milken Institute’s FasterCures, and a member of the Department of Health Policy Advisory Board at the Stanford University School of Medicine.

What is Alex M. Azar, II's net worth?: The estimated net worth of Alex M. Azar, II is at least $151.06 thousand as of September 16th, 2026. Mr. Azar, II owns 825 shares of Guardant Health stock worth more than $151,058 as of September 18th. This net worth estimate does not reflect any other assets that Mr. Azar, II may own. Learn More about Alex M. Azar, II's net worth.
How do I contact Alex M. Azar, II?: The corporate mailing address for Mr. Azar, II and other Guardant Health executives is 3100 Hanover Street, Palo Alto, CA, 94304. Guardant Health can also be reached via phone at (855) 698-8887 and via email at [email protected]. Learn More on Alex M. Azar, II's contact information.
Has Alex M. Azar, II been buying or selling shares of Guardant Health?: In the last ninety days, Alex M. Azar, II has sold $144,550.00 in Guardant Health stock. Most recently, Alex M. Azar, II sold 826 shares of the business's stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $175.00, for a transaction totalling $144,550.00. Following the completion of the sale, the director now directly owns 825 shares of the company's stock, valued at $144,375. Learn More on Alex M. Azar, II's trading history.
Who are Guardant Health's active insiders?: Guardant Health's insider roster includes Alex Azar, II (Director), Michael Bell (CFO), Derek Bertocci (CFO), Darya Chudova (CTO), Ian Clark (Director), Helmy Eltoukhy (CEO), Chris Freeman (Chief Commercial Officer, Oncology), Medina Hidalgo (Director), Meghan Joyce (Director), Kumud Kalia (Insider), Samir Kaul (Director), Steve Krognes (Director), Stanley Meresman (Director), Amelia Merrill (SVP), Terilyn Monroe (Insider), Myrtle Potter (Director), John Saia (Insider), Amirali Talasaz (COO), and Musa Tariq (Director). Learn More on Guardant Health's active insiders.
Are insiders buying or selling shares of Guardant Health?: During the last year, insiders at the sold shares 51 times. They sold a total of 1,341,181 shares worth more than $167,983,209.63. The most recent insider tranaction occured on September, 16th when Director Steve E. Krognes sold 6,674 shares worth more than $1,172,888.76. Insiders at Guardant Health own 5.6% of the company. Learn More about insider trades at Guardant Health.
Information on this page was last updated on 9/16/2026.

Alex M. Azar, II Insider Trading History at Guardant Health

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/16/2026	Sell	826	$175.00	$144,550.00	825

Alex M. Azar, II Buying and Selling Activity at Guardant Health

Guardant Health Company Overview

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Today's Range

Now: $183.10

$175.45

$183.51

50 Day Range

MA: $160.71

$143.62

$183.10

2 Week Range

Now: $183.10

$55.38

$183.51

Volume

1,858,277 shs

Average Volume

1,681,950 shs

Market Capitalization

$24.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57